Endoscopic Retroperitoneal Adrenalectomy for Adrenal Metastases
Objectives. To evaluate whether retroperitoneal approach for adrenalectomy is a safe and effective treatment for adrenal metastases (AM). Methods. From June 2004 to January 2014, nine consecutive patients with AM were treated with endoscopic retroperitoneal adrenalectomy (ERA). A retrospective study...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2014/806194 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568115166183424 |
|---|---|
| author | Gintaras Simutis Givi Lengvenis Virgilijus Beiša Kęstutis Strupas |
| author_facet | Gintaras Simutis Givi Lengvenis Virgilijus Beiša Kęstutis Strupas |
| author_sort | Gintaras Simutis |
| collection | DOAJ |
| description | Objectives. To evaluate whether retroperitoneal approach for adrenalectomy is a safe and effective treatment for adrenal metastases (AM). Methods. From June 2004 to January 2014, nine consecutive patients with AM were treated with endoscopic retroperitoneal adrenalectomy (ERA). A retrospective study was conducted, and clinical data, tumor characteristics, and oncologic outcomes were acquired and analyzed. Results. Renal cancer was the primary site of malignancy in 44.4% of cases. The mean operative time was 132 ± 10.4 min. There were 5 synchronous and 4 metachronous AM. One patient required conversion to transperitoneal laparoscopic procedure. No mortality or perioperative complications were observed. The median overall survival was 11 months (range: 2–42 months). Survival rates of 50% and 25% were identified at 1 and 3 years, respectively. At the end of the study, 4 patients were alive with a mean observed follow-up of 20 months. No patients presented with local tumor relapse or port-site metastases. Conclusions. This study shows that ERA is a safe and effective procedure for resection of AM and advances the surgical treatment of adrenal disease. The use of the retroperitoneal approach for adrenal tumors less than 6 cm can provide very favorable surgical outcomes. |
| format | Article |
| id | doaj-art-ed295bc7d7104ad8b42f9224ca022317 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-ed295bc7d7104ad8b42f9224ca0223172025-02-03T00:59:45ZengWileyInternational Journal of Endocrinology1687-83371687-83452014-01-01201410.1155/2014/806194806194Endoscopic Retroperitoneal Adrenalectomy for Adrenal MetastasesGintaras Simutis0Givi Lengvenis1Virgilijus Beiša2Kęstutis Strupas3Clinic of Gastroenterology, Nephrourology and Surgery, Center of Abdominal Surgery, Faculty of Medicine, Vilnius University, Santariškiu 2, 08661 Vilnius, LithuaniaFaculty of Medicine, Vilnius University, M.K.Čiulionio 21, 03101 Vilnius, LithuaniaClinic of Gastroenterology, Nephrourology and Surgery, Center of Abdominal Surgery, Faculty of Medicine, Vilnius University, Santariškiu 2, 08661 Vilnius, LithuaniaClinic of Gastroenterology, Nephrourology and Surgery, Center of Abdominal Surgery, Faculty of Medicine, Vilnius University, Santariškiu 2, 08661 Vilnius, LithuaniaObjectives. To evaluate whether retroperitoneal approach for adrenalectomy is a safe and effective treatment for adrenal metastases (AM). Methods. From June 2004 to January 2014, nine consecutive patients with AM were treated with endoscopic retroperitoneal adrenalectomy (ERA). A retrospective study was conducted, and clinical data, tumor characteristics, and oncologic outcomes were acquired and analyzed. Results. Renal cancer was the primary site of malignancy in 44.4% of cases. The mean operative time was 132 ± 10.4 min. There were 5 synchronous and 4 metachronous AM. One patient required conversion to transperitoneal laparoscopic procedure. No mortality or perioperative complications were observed. The median overall survival was 11 months (range: 2–42 months). Survival rates of 50% and 25% were identified at 1 and 3 years, respectively. At the end of the study, 4 patients were alive with a mean observed follow-up of 20 months. No patients presented with local tumor relapse or port-site metastases. Conclusions. This study shows that ERA is a safe and effective procedure for resection of AM and advances the surgical treatment of adrenal disease. The use of the retroperitoneal approach for adrenal tumors less than 6 cm can provide very favorable surgical outcomes.http://dx.doi.org/10.1155/2014/806194 |
| spellingShingle | Gintaras Simutis Givi Lengvenis Virgilijus Beiša Kęstutis Strupas Endoscopic Retroperitoneal Adrenalectomy for Adrenal Metastases International Journal of Endocrinology |
| title | Endoscopic Retroperitoneal Adrenalectomy for Adrenal Metastases |
| title_full | Endoscopic Retroperitoneal Adrenalectomy for Adrenal Metastases |
| title_fullStr | Endoscopic Retroperitoneal Adrenalectomy for Adrenal Metastases |
| title_full_unstemmed | Endoscopic Retroperitoneal Adrenalectomy for Adrenal Metastases |
| title_short | Endoscopic Retroperitoneal Adrenalectomy for Adrenal Metastases |
| title_sort | endoscopic retroperitoneal adrenalectomy for adrenal metastases |
| url | http://dx.doi.org/10.1155/2014/806194 |
| work_keys_str_mv | AT gintarassimutis endoscopicretroperitonealadrenalectomyforadrenalmetastases AT givilengvenis endoscopicretroperitonealadrenalectomyforadrenalmetastases AT virgilijusbeisa endoscopicretroperitonealadrenalectomyforadrenalmetastases AT kestutisstrupas endoscopicretroperitonealadrenalectomyforadrenalmetastases |